This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

mRNA Technologies, Therapeutics & Vaccines Digital Week
June 28-30, 2023
FREE TO ATTEND ★ VIRTUAL EVENTDelivered in Eastern Standard Time (EST)
June 28-30, 2023
FREE TO ATTEND ★ VIRTUAL EVENT,
Delivered in Eastern Standard Time (EST)

Industry Leaders & Service Providers will showcase the power and diversity of mRNA technologies and applications across discovery, R&D, manufacturing & delivery

Delivered as a 3-Day Complimentary Webcast Series

Registration Page Opening Soon!

WHY ATTEND A DIGITAL WEEK?

Time and Cost Efficient

You will save valuable time and money because there is no need to travel and no registration fee.

Focused and Timely Learning

You will receive the latest "hot" and timely data from the best in the industry -- focused solely on mRNA. Our webinars feature presentations from world-renowned industry leaders as well as scientific technology demonstrations presented by leading scientists and engineers working directly with the latest mRNA technology to provide comprehensive update and insights.

Convenience

You can participate in a webinar from a location of your choosing – your home, your office, or a client/customer location. We also offer the webinar sessions on-demand for you to watch on your own time, whether you couldn't make a session or you want to rewatch it.

Key Themes for 2022 Digital Week

mRNA Therapeutics and Vaccines in Discovery, Preclinical and Clinical Development

mRNA Delivery and Formulation

CMC and Manufacturing Strategies and Capabilities for mRNA Projects

Novel mRNA Technologies and Applications

June 28-30, 2023
FREE TO ATTEND ★ VIRTUAL EVENT,
Delivered in Eastern Standard Time (EST)

Interested in Sponsoring mNRA Digital Week?

This is a great opportunity to engage directly with decision makers in the oligonucleotide and peptide market space, focused specifically on mRNA.